Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Top Pharmaceutical Stocks for 2013: Crown Marketing Inc., Pfizer Inc., Merck & Co. Inc., and Eli Lilly and Company

January 16, 2013

NEW YORK, January 16, 2013 /PRNewswire/ –

PremierEquityReports.com [http://www.premierequityreports.com ] provides investors
with quality research and analysis on U.S. equities on the move and today issues a report
on the top pharmaceutical companies for 2013: Crown Marketing Inc. (OTCBB: CWNM), Pfizer
Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), and Eli Lilly and Company (NYSE: LLY).

Crown Marketing Inc. (OTCBB: CWNM) has recently patented a controlled drug delivery
technology that aims not only to improve the safety and pharmacokinetics of
controlled-release medication, but also to streamline the manufacturing process for
existing facilities without significantly increasing costs. Crown Marketing is seeking to
change the time-release process entirely, providing a true 24-hour sustained-release
delivery system.

Crown Marketing has also announced that the smart drug delivery revolution has
officially arrived.

Read the entire press release issued by Crown Marketing Inc. (OTCBB: CWNM) here:

http://finance.yahoo.com/news/crown-marketing-announces-smart-drug-175924186.html

Pfizer Inc. (NYSE: PFE) has been the buzz of Wall Street with rumors circulating that
the company will split its drug division in two. President Geno Germano said, “…probably
going to evolve to two, where there’s the innovative business and the value business,” in
a January 8th interview. This news excites analysts because a split would make sense and
would turn eyes away from its pipeline and base business to financial engineering.

TheStreet.com, website of infamous stock picker Jim Cramer, has reiterated a buy
rating on Pfizer with a rating score of A-.

Read the entire press release issued by TheStreet.com about Pfizer Inc. (NYSE: PFE)
here:

http://www.thestreet.com/story/11813258/1/pfizer-inc-stock-buy-recommendation-reiterated-pfe.html?puc=yahoo&cm_ven=YAHOO

Merck & Co. Inc. (NYSE: MRK) recently announced that it is taking its cholesterol
management drug, Tredaptive, off the market. The decision was based on preliminary data
from a long term safety study.

Read the entire press release about Merck & Co. Inc. (NYSE: MRK) here:

http://finance.yahoo.com/news/merck-stop-selling-tredaptive-231852003.html

Sam Isaly’s Orbimed Advisors, a large health care fund investing in healthcare
companies, reported a position of 4.6 million shares in Merck, a 33% increase from three
months earlier.

Eli Lilly and Company’s (NYSE: LLY) brain-plaque diagnostic was approved for use in
adult patients by European health regulators on Tuesday. Their imaging agent is used to
detect brain plaques that are considered a possible cause of Alzheimer’s disease. This
radioactive diagnostic called Amyvid, was approved for use in the United States last
April. The brain plaques were previously only detectable through autopsy.

Read the entire press release about Eli Lilly and Company (NYSE: LLY) here:

http://www.reuters.com/article/2013/01/15/lilly-diagnostic-idUSL2N0AKJRH20130115?feedType=RSS&feedName=rbssHealthcareNews&rpc=43

Sign up to receive detailed reports and stock picks at
http://www.PremierEquityReports.com. For real-time trade updates, follow our award
winning hedge fund trader on Twitter @StockBrainiac. Premier Equity Reports also offers a
FREE text message alert service to ensure that you receive all alerts. Simply text
“reports” to 63566.

Premier Equity Reports is the U.S. leader in equity reports, offering quality reports
to investors looking for the most undervalued companies in the market. Premier Equity
Reports provides its subscribers with timely information and exclusive analysis on U.S.
companies with substantial upside potential. Premier Equity Reports is the #1 free
financial newsletter in the industry. Sign up now and see why thousands have joined
already.

Disclosure: PremierEquityReports.com is not a registered investment advisor and
nothing contained in any materials should be construed as a recommendation to buy or sell
securities. Investors should always conduct their own due diligence with any potential
investment. Premier Equity Reports is a wholly owned entity of Equities Awareness Group
LLC. Equities Awareness Group LLC has been compensated one hundred thousand dollars for
marketing awareness on Crown Marketing Inc. Please read our report and visit our website,
for complete risks and disclosures.

        Contact Information:
        Equities Awareness Group LLC
        Michael Perinotti
        mike@equitiesag.com

http://www.EquitiesAG.com

        +1-201-917-5934
        Third Party Publishing Provider: FNNewswire, a FN Media Group, LLC Company.

SOURCE Equities Awareness Group LLC


Source: PR Newswire